Literature DB >> 7526873

Early lesion development in the aortas of rabbits fed low-fat, cholesterol-free, semipurified casein diet.

M Richardson1, E M Kurowska, K K Carroll.   

Abstract

The initial endothelial morphological alterations and the development of raised, lipid-containing lesions in rabbit aortas were examined after 1 and 3 months on a casein-enriched, semipurified, cholesterol-free diet. The alterations were compared with those in rabbits fed soy-protein in the place of casein and with age-matched, chow-fed, control animals. Using immunohistochemistry macrophages, T-lymphocytes, and smooth muscle cells were identified in the lesions, and an expression of leukocyte adhesion molecules, VCAM-1, ICAM-1 and, occasionally, E-selectin was seen in sections of the aortas of casein-fed rabbits. The initial alterations in the endothelium appear to include evidence of endothelial injury and white blood cell adhesion. No evidence of extracellular liposome formation was observed. This model of atherogenesis is consistent with endothelial injury being an important component of diet-induced atherogenesis and has similarities to human atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526873     DOI: 10.1016/0021-9150(94)90018-3

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  3 in total

1.  Rabbit model for Chlamydia pneumoniae infection.

Authors:  I W Fong; B Chiu; E Viira; M W Fong; D Jang; J Mahony
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

2.  Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits.

Authors:  K Laitinen; A Laurila; L Pyhälä; M Leinonen; P Saikku
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

3.  Ribonucleotide reductase inhibitors reduce atherosclerosis in a double-injury rabbit model.

Authors:  Laura D Gallaugher; Jon C Henry; Patrick N Kearns; Howard L Elford; Valerie K Bergdall; Arturo J Cardounel
Journal:  Comp Med       Date:  2009-12       Impact factor: 0.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.